标题
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
作者
关键词
-
出版物
NATURE MEDICINE
Volume 24, Issue 11, Pages 1649-1654
出版商
Springer Nature America, Inc
发表日期
2018-10-04
DOI
10.1038/s41591-018-0197-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
- (2018) Rodabe N Amaria et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab Adjuvant Therapy in Melanoma
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
- (2016) Hiroyuki Inoue et al. OncoImmunology
- Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
- (2015) Elena Provenzano et al. MODERN PATHOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications
- (2014) Andy Rimmer et al. NATURE GENETICS
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- (2011) Mark A DePristo et al. NATURE GENETICS
- Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads
- (2009) K. Ye et al. BIOINFORMATICS
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search